Clinical Scorecard: Beyond Correction
At a Glance
| Category | Detail |
|---|---|
| Condition | Ocular and systemic disease management |
| Key Mechanisms | Integration of biosensors, drug delivery systems, and augmented reality in contact lenses |
| Target Population | Individuals requiring vision correction and those with ocular diseases |
| Care Setting | Ophthalmology and wearable health technology |
Key Highlights
- Smart contact lenses (CLs) enable noninvasive biosensing of biomarkers in tear fluid.
- Continuous monitoring of intraocular pressure (IOP) for glaucoma management.
- Advanced drug delivery mechanisms improve therapeutic efficacy compared to traditional eye drops.
- 3D printing allows for customization and integration of smart features in CLs.
- AI enhances diagnostic capabilities and personalized treatment approaches.
Guideline-Based Recommendations
Diagnosis
- Utilize smart CLs for continuous monitoring of IOP and biomarkers for ocular diseases.
Management
- Implement smart CLs for drug delivery in conditions like glaucoma and dry eye disease.
Monitoring & Follow-up
- Employ smart CLs for real-time monitoring of tear fluid biomarkers and ocular conditions.
Risks
- Address challenges related to biocompatibility, power supply, and regulatory approval.
Patient & Prescribing Data
Patients with diabetes, glaucoma, dry eye disease, and those requiring ocular drug delivery.
Smart CLs can provide noninvasive monitoring and targeted drug delivery, enhancing patient outcomes.
Clinical Best Practices
- Collaborate across disciplines to address technical and regulatory challenges in smart CL development.
- Focus on patient comfort and biocompatibility in the design of smart CLs.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.